This theory has been supported by groups who have induced resistance to TKIs in imatinib-sensible CML cell lines cloned by limiting dilution; they have found the appearance of BCR-ABL gene amplification and of point mutations in the kinase domain that were not present in the original cells [60]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.